Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Subscribe To Our Newsletter & Stay Updated
